safety

For pediatric patients 1 year and older with thrombocytopenia in persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1

HELP LIFT PLATELET COUNTS AND LIGHTEN 
TREATMENT LIMITATIONS

Doptelet and Doptelet Sprinkle offer a fast and durable platelet response and are the only oral TPO-RAs without dietary restrictions, liver monitoring, or treatment injections. Doptelet and Doptelet Sprinkle are not used to make platelet counts normal.1-3*†‡

Doptelet and Doptelet Sprinkle

Doptelet Sprinkle is indicated for patients aged ≥1 and <6 years. Doptelet tablets are indicated for patients aged 6 and older. Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis.1

alt

Coming soon: Doptelet Sprinkle

Doptelet Sprinkle has been approved for persistent or chronic pediatric ITP for kids aged ≥1 to <6 years—Sobi is working to make it available as soon as possible.1

What makes Doptelet and Doptelet Sprinkle different

ASH guidelines recommend selecting treatment options that align with patient preferences, as mode of administration can play a key role in adherence.4

No food-type restrictions

No food-type
restrictions

Minerals like calcium or magnesium won’t impact the effectiveness of Doptelet or Doptelet Sprinkle. That means your pediatric patients can have any food they want, at any time. Doptelet tablet must be taken with food, and Doptelet Sprinkle must be taken with any soft food or liquid.1§

No liver monitoring

No liver monitoring

Doptelet and Doptelet Sprinkle do not require additional liver function monitoring; no significant hepatotoxicity has been seen in clinical trials.1,5,6

No treatment injections

No treatment injections

Doptelet is an oral medication that can be taken anytime, anywhere, in two forms—tablet or oral granules (coming soon)—without adding trips to the doctor for treatment.1II

Remember to monitor drug interactions and platelet response.II

Fits their schedule

Fits their schedule

Your patient’s caregiver can choose when to give Doptelet or Doptelet Sprinkle, as long as it’s at the same time each day.1

No cataract precautions

No eye exams

No eye exams are required before starting and during treatment with Doptelet or Doptelet Sprinkle.7

No food-type restrictions

No food-type
restrictions

Minerals like calcium or magnesium won’t impact the effectiveness of Doptelet or Doptelet Sprinkle. That means your pediatric patients can have any food they want, at any time. Doptelet tablet must be taken with food, and Doptelet Sprinkle must be taken with any soft food or liquid.1§

No liver monitoring

No liver monitoring

Doptelet and Doptelet Sprinkle do not require additional liver function monitoring; no significant hepatotoxicity has been seen in clinical trials.1,5,6

No treatment injections

No treatment injections

Doptelet is an oral medication that can be taken anytime, anywhere, in two forms—tablet or oral granules (coming soon)—without adding trips to the doctor for treatment.1II

Remember to monitor drug interactions and platelet response.II

Fits their schedule

Fits their schedule

Your patient’s caregiver can choose when to give Doptelet or Doptelet Sprinkle, as long as it’s at the same time each day.1

No cataract precautions

No eye exams

No eye exams are required before starting and during treatment with Doptelet or Doptelet Sprinkle.7

When first-line treatments fall short, TPO-RAs step in

When first-line treatments are no longer effective, second-line therapies can be considered to increase platelet counts. TPO-RAs like Doptelet and Doptelet Sprinkle activate the TPO receptor to help increase platelet production in persistent or chronic ITP.1,4,8

Why choose TPO-RAs?

Approved for pediatric patients with persistent or chronic ITP who don’t respond to first-line treatment1,4

Recommended as second-line therapy by ASH4

Supported for use after initial therapy in the International Consensus Report for primary ITP9

How Doptelet and Doptelet Sprinkle work

Doptelet and Doptelet Sprinkle stimulate platelet production without blocking native TPO.1

  • Doptelet, in both tablet and oral granule forms, is an oral TPO-RA that binds to the c-Mpl (TPO) receptor on hematopoietic stem cells1,10,11
  • Its binding site is distinct from endogenous TPO and other TPO-RAs, activating different signal transduction pathways1,10,11
  • This results in JAK-STAT pathway activation, megakaryocyte maturation, and increased platelet production1,10,11
  • Because it doesn’t compete with native TPO, Doptelet, in both tablet and oral granule forms, allows for an additive effect on platelet counts1,10,11
*A durable response is defined as the proportion of patients achieving at least 6 out of 8 weekly platelet counts ≥50x109/L during the last 8 weeks of the 12-week core phase treatment period in the absence of rescue therapy.1
†The durable platelet response rate was significantly greater in avatrombopag-treated patients compared with those receiving placebo (27.8% vs 0.0%; P=0.0077).1
‡55.6% of patients treated with Doptelet or Doptelet Sprinkle were able to achieve a platelet count of ≥50x109/L in as few as 8 days.1
§Studied mixture options include liquids (water, whole milk, orange juice, etc) and soft foods (yogurt, applesauce, etc). Doptelet Sprinkle does not dissolve in mixture.1
IIPlatelet monitoring required. After initiating therapy with Doptelet or Doptelet Sprinkle, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts weekly for at least 4 weeks following discontinuation of treatment. Doptelet and Doptelet Sprinkle are not used to make platelet counts normal.1

ASH=American Society of Hematology; JAK-STAT=Janus kinase-signal transducer and activator of transcription; TPO=thrombopoietin; TPO-RA=thrombopoietin receptor agonist. 

Where would you like to go next?

I'm interested in the clinical profile of Doptelet

I’m interested in the clinical profiles of Doptelet and Doptelet Sprinkle

VIEW EFFICACY

alt

I’m reviewing how to dose Doptelet or Doptelet Sprinkle

SEE DOSING

I’m looking for access and financial support information

I’m looking for access and financial support information 

EXPLORE

  1. DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
  2. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023.
  3. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; 2025.
  4. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
  5. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
  6. Bussel J, Allen LF, Aggarwal K, Vredenburg M, Tian W, Liebman W. Lack of clinically significant hepatotoxicity in patients with chronic immune thrombocytopenia treated with the novel, oral thrombopoietin receptor antagonist avatrombopag: pooled safety analysis of four clinical studies. Poster presented at: ISTH Conference 2019. July 6-10, 2019; Melbourne, Australia. Abstract PB0418.
  7. Data on file. Clinical study report for AVA-PED-301. 2025: Sobi, Inc.
  8. NORD (National Organization for Rare Disorders) website: immune thrombocytopenia. Available at: https://rarediseases.org/rare-diseases/immune-thrombocytopenia/. Accessed May 12, 2021.
  9. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
  10. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16.
  11. Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022;53:100909.